[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Scholar Rock Holding Corp (SRRK)

Scholar Rock Holding Corp (SRRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,093,976
  • Shares Outstanding, K 121,785
  • Annual Sales, $ 0 K
  • Annual Income, $ -377,940 K
  • EBIT $ -406 M
  • EBITDA $ -408 M
  • 60-Month Beta 0.69
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 26.68

Options Overview Details

View History
  • Implied Volatility 61.98% (+6.85%)
  • Historical Volatility 50.00%
  • IV Percentile 41%
  • IV Rank 11.45%
  • IV High 152.07% on 09/22/25
  • IV Low 50.33% on 01/22/26
  • Expected Move (DTE 23) 2.30 (3.94%)
  • Put/Call Vol Ratio 0.33
  • Today's Volume 184
  • Volume Avg (30-Day) 404
  • Put/Call OI Ratio 0.58
  • Today's Open Interest 11,626
  • Open Int (30-Day) 17,462
  • Expected Range 55.96 to 60.55

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.87
  • Number of Estimates 6
  • High Estimate $-0.80
  • Low Estimate $-0.94
  • Prior Year $-0.90
  • Growth Rate Est. (year over year) +3.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
45.73 +27.38%
on 08/03/26
59.48 -2.07%
on 08/25/26
+10.58 (+22.19%)
since 07/24/26
3-Month
43.23 +34.74%
on 06/11/26
59.48 -2.07%
on 08/25/26
+10.12 (+21.03%)
since 05/22/26
52-Week
27.07 +115.18%
on 11/07/25
59.48 -2.07%
on 08/25/26
+24.92 (+74.77%)
since 08/25/25

Most Recent Stories

More News
Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan

Under FDA guidance, Scholar Rock has successfully removed Catalent Indiana LLC (part of Novo Nordisk) as a commercial fill-finish facility from apitegromab Biologics License Application (BLA) for spinal...

SRRK : 58.25 (+0.09%)
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 51,947 shares of its common stock to twelve newly hired employees,...

SRRK : 58.25 (+0.09%)
Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

Today, August 7, 2026, Scholar Rock received customer notification from Catalent Indiana LLC (part of Novo Nordisk) that FDA classified the April 2026 site inspection of Catalent Indiana fill-finish facility...

SRRK : 58.25 (+0.09%)
Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA) review by FDA continues to advance with two fill-finish facilities, representing two independent paths to an FDA approval...

SRRK : 58.25 (+0.09%)
Scholar Rock's BLA Acceptance Masks the Real Commercial Execution Risk Ahead

Barchart Research What to Expect from SRRK Earnings SRRK Generated August 5, 2026 Current Price $47.97 EPS Estimate $$-0.84 Consensus Rating Strong Buy Average Move 5.75% Scholar Rock's BLA Acceptance...

SRRK : 58.25 (+0.09%)
Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating...

SRRK : 58.25 (+0.09%)
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm

NEW YORK , July 28, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Scholar Rock Holding Corp (NASDAQ: SRRK)...

SRRK : 58.25 (+0.09%)
Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)

July 2026 CHMP meeting commences today, prior to FDA inspection classification for Catalent Indiana LLC (part of Novo Nordisk) fill-finish facility Apitegromab...

SRRK : 58.25 (+0.09%)
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 118,586 shares of its common stock to eleven newly hired employees,...

SRRK : 58.25 (+0.09%)
Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026

Scholar Rock (NASDAQ: SRRK) today announced that it will report second quarter 2026 financial results on Thursday, August 6, 2026, before the financial markets open. The Company will host...

SRRK : 58.25 (+0.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Scholar Rock Holding Corporation is a biopharmaceutical company. It focused on the discovery and development of medicines for treatment of serious diseases. The company's product candidate includes SRK-015 and BMP6 which is in pre-clinical stage. Scholar Rock Holding Corporation is based in Cambridge,...

See More

Key Turning Points

3rd Resistance Point 61.89
2nd Resistance Point 60.68
1st Resistance Point 59.47
Last Price 58.25
1st Support Level 57.05
2nd Support Level 55.84
3rd Support Level 54.63

See More

52-Week High 59.48
Last Price 58.25
Fibonacci 61.8% 47.10
Fibonacci 50% 43.28
Fibonacci 38.2% 39.45
52-Week Low 27.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.